RNA anti-CD19 CAR T cells

RNA anti-CD19 CAR T cells are a form of chimeric antigen receptor (CAR) T-cell therapy in which autologous or allogeneic human T lymphocytes are genetically modified ex vivo using messenger RNA (mRNA) or other forms of synthetic RNA to transiently express a CAR targeting the CD19 antigen. The CD19-directed CAR typically consists of an extracellular single-chain variable fragment (scFv) derived from an antibody specific for CD19, fused to intracellular signaling domains such as CD3ζ and co-stimulatory molecules like 4-1BB or CD28. Unlike conventional viral vector-based approaches that result in permanent genetic modification, the use of mRNA allows for transient expression of the CAR on the surface of infused T-cells, potentially improving safety by reducing long-term risks and allowing titratable control over activity[2][9]. These therapies are being investigated primarily for B-cell malignancies such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and increasingly for autoimmune diseases where pathogenic B-cells play a role[2][6][9]. The mechanism involves recognition and killing of CD19-expressing malignant or autoreactive B-cells by engineered cytotoxic T-cells.

Other names

mRNA-based anti-CD19 CAR T cellsRNA electroporated CD19CAR-CD3zeta-4-1BB-expressing T cells